I-Chin Wu

TL;DR: The interplay between glucose, ApoJ and HCV virion production is investigated, which facilitates infectious HCV particle production via stabilization of core/NS5A, which might surround LDs at the ER-Golgi membrane contact site.

TL;DR: This retrospective analysis demonstrated that HBeAg‐negative CHB patients treated with entecavir responded similarly irrespective of baseline ALT level, however, H beAg‐positive patients with mildly elevated ALT responded less well to treatment with entECavir than did those with ALT greater than 2 × ULN.

TL;DR: This study reveals that LPL is an anti-HCV factor, and that apoC-III in VLDL and LVPs reduces the LPL-mediated inhibition of HCV infection.

TL;DR: Although one‐year ETV or ADV treatment is insufficient for cccDNA eradication, oral antiviral therapies may improve liver histology, probably by suppressing intrahepatic ccc DNA.

TL;DR: Aberrant serum IgG-Fc glycosylation in CHB, which is highly associated with histological liver damage, affects IgG opsonizing activity and can be reversed by antiviral therapy.